LAS VEGAS, July 21, 2017 /PRNewswire/ --
Senate Republicans introduced a revised version of the health care repeal aiming to replace the Affordable Care Act earlier this month. Repealing the law was a top priority for Mr. Trump and Republicans in Congress, claiming the law has driven up premiums and forced consumers to buy insurance they cannot afford and do not want.
The rewritten package would add $70 billion to the $112 billion for states to use to help curb the growth of premiums and consumers' other out-of-pocket costs. It also includes $45 billion for states to combat the misuse of drugs like opioids. What isn't clear on the new health care repeal is how it will affect regenerative medicine and advances in biotechnology. Regenerative medicine is a life changing area of medicine that has the potential to fully heal damaged organs and tissues.
Regenerative medicine aims to improve the quality of life for patients suffering from life threatening diseases. Governments, scientists, universities, and private companies work with this powerful technology to create new body parts from a patient's own cells and tissues. While the United States is in limbo in terms of government health care reform, it is essential to track private biotechnology companies as they navigate through clinical trials and new drug implementation. Biotech companies furthering the regenerative medical field include: Endonovo Therapeutics (OTCQB: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), FibroGen, Inc. (NASDAQ: FGEN), OraSure Technologies, Inc. (NASDAQ: OSUR) and Capricor Therapeutics (NASDAQ: CAPR).
Endonovo Therapeutics (OTCQB: ENDV) ENDV is an innovative biotechnology company implementing a bioelectronic approach to regenerative medicine. They operate as an intellectual property licensing and commercialization company and a biomedical research and development company, allowing them to license and develop life-changing regenerative medical products across several platforms. Their Immunotronic technology uses non-invasive electromagnetic pulses to deliver electrical stimulation via inductive coupling to the nervous system and cells. At the end of June, ENDV released an open letter to shareholders providing updates on their pre-clinical study in Myocardial Infraction.
Pulse Biosciences, Inc. (NASDAQ: PLSE) a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), will host its quarterly investor conference call on July 27, 2017, at 1:30 p.m. PDT / 4:30 p.m. EDT. The company will provide an update on the clinical advancement of the PulseTxTM System, including progress of the clinical study evaluating NPS for the treatment of seborrheic keratosis (SK), as well as the status of the 510(k) submission from earlier this year. The company will also provide an update on recent financial results and developments, including financial results for the quarter ended June 30, 2017.
FibroGen, Inc. (NASDAQ: FGEN) a science-based biopharmaceutical company, recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to pamrevlumab, the company's first-in-class antibody, for the treatment of pancreatic cancer.
OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2017 second quarter financial results, 2017 third quarter financial guidance and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, August 2, 2017.
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to CAP-1002, Capricor's development candidate for the treatment of Duchenne muscular dystrophy, a debilitating genetic disorder characterized by progressive weakness and chronic inflammation of skeletal, heart, and respiratory muscles. The Rare Pediatric Disease Designation, as well as the Orphan Drug Designation previously granted to CAP-1002 by the FDA, covers the broad treatment of DMD. Upon receiving market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher.
DISCLAIMER: Microcap Speculators (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link: http://microcapspeculators.com/disclaimer/
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
Media Contact e-mail: FN Media Group, LLC [email protected] +1(954)345-0611
Microcap Speculators: Email: [email protected] Phone: +1-702-720-6310 Website: http://microcapspeculators.com/
SOURCE Microcap Speculators
Advertisement
Senate Republicans introduced a revised version of the health care repeal aiming to replace the Affordable Care Act earlier this month. Repealing the law was a top priority for Mr. Trump and Republicans in Congress, claiming the law has driven up premiums and forced consumers to buy insurance they cannot afford and do not want.
Advertisement
The rewritten package would add $70 billion to the $112 billion for states to use to help curb the growth of premiums and consumers' other out-of-pocket costs. It also includes $45 billion for states to combat the misuse of drugs like opioids. What isn't clear on the new health care repeal is how it will affect regenerative medicine and advances in biotechnology. Regenerative medicine is a life changing area of medicine that has the potential to fully heal damaged organs and tissues.
Regenerative medicine aims to improve the quality of life for patients suffering from life threatening diseases. Governments, scientists, universities, and private companies work with this powerful technology to create new body parts from a patient's own cells and tissues. While the United States is in limbo in terms of government health care reform, it is essential to track private biotechnology companies as they navigate through clinical trials and new drug implementation. Biotech companies furthering the regenerative medical field include: Endonovo Therapeutics (OTCQB: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), FibroGen, Inc. (NASDAQ: FGEN), OraSure Technologies, Inc. (NASDAQ: OSUR) and Capricor Therapeutics (NASDAQ: CAPR).
Endonovo Therapeutics (OTCQB: ENDV) ENDV is an innovative biotechnology company implementing a bioelectronic approach to regenerative medicine. They operate as an intellectual property licensing and commercialization company and a biomedical research and development company, allowing them to license and develop life-changing regenerative medical products across several platforms. Their Immunotronic technology uses non-invasive electromagnetic pulses to deliver electrical stimulation via inductive coupling to the nervous system and cells. At the end of June, ENDV released an open letter to shareholders providing updates on their pre-clinical study in Myocardial Infraction.
Pulse Biosciences, Inc. (NASDAQ: PLSE) a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), will host its quarterly investor conference call on July 27, 2017, at 1:30 p.m. PDT / 4:30 p.m. EDT. The company will provide an update on the clinical advancement of the PulseTxTM System, including progress of the clinical study evaluating NPS for the treatment of seborrheic keratosis (SK), as well as the status of the 510(k) submission from earlier this year. The company will also provide an update on recent financial results and developments, including financial results for the quarter ended June 30, 2017.
FibroGen, Inc. (NASDAQ: FGEN) a science-based biopharmaceutical company, recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to pamrevlumab, the company's first-in-class antibody, for the treatment of pancreatic cancer.
OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2017 second quarter financial results, 2017 third quarter financial guidance and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, August 2, 2017.
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to CAP-1002, Capricor's development candidate for the treatment of Duchenne muscular dystrophy, a debilitating genetic disorder characterized by progressive weakness and chronic inflammation of skeletal, heart, and respiratory muscles. The Rare Pediatric Disease Designation, as well as the Orphan Drug Designation previously granted to CAP-1002 by the FDA, covers the broad treatment of DMD. Upon receiving market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher.
DISCLAIMER: Microcap Speculators (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link: http://microcapspeculators.com/disclaimer/
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
Media Contact e-mail: FN Media Group, LLC [email protected] +1(954)345-0611
Microcap Speculators: Email: [email protected] Phone: +1-702-720-6310 Website: http://microcapspeculators.com/
SOURCE Microcap Speculators
